Toronto Stock Exchange Symbol: MS
EDMONTON, May 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), will hold its Annual General Meeting on Friday, May 9, 2008, at 2:00 p.m. (MT), 4:00 p.m. (ET).
A live audio webcast of the conference call will be available at http://www.biomsmedical.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.
Members of the professional investment community are invited to
participate in the conference call by telephone.
DATE: Friday, May 9, 2008
TIME: 2:00p.m. (Mountain Time), 4:00 p.m. (Eastern Time)
DIAL IN NUMBER: 416 644-3430 or 1 800-814-4857
TAPED REPLAY: 1 877-289-8525 or 416 640-1917; available from
May 9, 2008 until May 16, 2008 at midnight
REFERENCE NUMBER: 21271314
About BioMS Medical Corp.
------------------------- BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved